<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182919</url>
  </required_header>
  <id_info>
    <org_study_id>COA-CREC036/2019</org_study_id>
    <nct_id>NCT04182919</nct_id>
  </id_info>
  <brief_title>&quot;Efficacy and Safety of Phlai Capsule Compared to Placebo as the Treatment in Allergic Rhinitis Patients&quot;</brief_title>
  <official_title>&quot;Efficacy and Safety of Phlai Capsule Compared to Placebo as the Treatment in Allergic Rhinitis Patients&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Government Pharmaceutical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Zingiber cassumunar Roxb., frequently known as Phlai in Thai, has been safely
      used as an antihistaminic and anti-inflammatory drug in Thai traditional medicine. Individual
      with allergic rhinitis may have positive response to Phlai.

      Objective: Investigators assessed the efficacy and safety of Phlai as a treatment for
      allergic rhinitis Design: The study was a 1-month, double-blind, randomized, parallel-group,
      intent-to-treat, multicenter, controlled trial in 267 patients at 7 hospitals in Thailand.
      Skin prick test-positive adults with allergic rhinitis ages 18 to 50 who were randomized into
      3 groups (Phlai 8mg/d, Phlai 4mg/d, placebo).

      Main outcome measures: Primary outcome was defined: improvement of total 5 symptoms scores
      (nasal obstruction, rhinorrhea, sneezing, itchy nose, itchy eyes) over a 4-week interval
      among Phlai 8mg/d, Phlai 4mg/d and placebo. Secondary endpoints were: assessments of
      rhinoconjunctivitis quality of life questionnaire, peak inspiratory nasal flow, nasal
      examination, adverse events, AST, ALT, Creatinine and BUN over a period of 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participant in each arm will take medication provided by care providers who also do not know what kind of this medication</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Participant, care provider and investigator, outcomes assessor in each site do not know what kind of medication in each package.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total five symptoms score (T5SS)</measure>
    <time_frame>24 hours</time_frame>
    <description>T5SS: (nasal obstruction, rhinorrhea, sneezing, itchy nose, itchy eyes). For each symptom:
0: no symptoms
mild
moderate
severe. Participants assess T5SS everyday. Self assessment twice a day Bedtime : reflective symptoms score Morning :instantaneous symptoms score. The mean score of two assessment is the T5SS. Investigator will calculate the mean T5SS in the follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rhinoconjunctivitis Quality of Life Questionaire (RCQ-36) Thai version</measure>
    <time_frame>4 weeks</time_frame>
    <description>This questionnaire is designed to find out how your health and well-being have been affected by rhinoconjunctivitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak inspiratory nasal flow (PNIF)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Use to measure nasal airflow during maximal inspiration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal examination</measure>
    <time_frame>2 weeks</time_frame>
    <description>Outcome assessor in each site will check the three symptoms: nasal swelling, pale and nasal discharge by anterior rhinoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 weeks</time_frame>
    <description>Sedation, dizziness, dry mouth, headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST Level</measure>
    <time_frame>4 weeks</time_frame>
    <description>Liver function test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT Level</measure>
    <time_frame>4 weeks</time_frame>
    <description>Liver function test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine level</measure>
    <time_frame>4 weeks</time_frame>
    <description>Renal function test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BUN</measure>
    <time_frame>4 weeks</time_frame>
    <description>Renal function test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophils blood level</measure>
    <time_frame>4 weeks</time_frame>
    <description>CBC test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte blood level</measure>
    <time_frame>4 weeks</time_frame>
    <description>CBC test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>4 weeks</time_frame>
    <description>CBC test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet level</measure>
    <time_frame>4 weeks</time_frame>
    <description>CBC test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">267</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phlai 2 capsules (compound D 8 mg) od evening after meal x 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phlai 1 capsules (compound D 4 mg) and placebo 1 capsule od evening after meal x 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2 capsules od evening after meal x 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phlai</intervention_name>
    <description>Each capsule contains 4 mg compound D. Using orally in the evening everyday in 4 weeks</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Zingiber cassumunar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Like Phlai capsule extract : :PVP K30, Calcium carbonate, Dibasic calcium phosphate, Sodium starch glycolate, Colloidal silicon dioxide, Ethanol 96%, Purified water, Magnesium stearate. Not having compound D. Using orally in the evening everyday in 4 weeks</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-50 years old

          -  Allergic rhinitis following diagnostic criteria of ARIA guideline

          -  Reflective total 5 symptoms score 2-10 per day for 3 consecutive days (total score=15)
             and not greater than 10 in any days during the past week

          -  Positive skin prick test to at least one aeroallergen: wheal size â‰¥ 3 mm greater than
             negative control

          -  Not receiving intranasal corticosteroid + intra antihistamine for 2 weeks , intranasal
             corticosteroid for 2 weeks, systemic corticosteroid for 4 weeks, antihistamine for 1
             week, nasal decongestant for 1 week and leukotriene receptor antagonists for 1 week

        Exclusion Criteria:

          -  Serious medical underlying diseases e.g. COPD, Heart disease, Chronic renal failure,
             chronic hepatic failure

          -  Allergic rhinitis and asthma which require immunotherapy

          -  Receiving antidepressants, sedative, anxiolytic, opioids, neuroleptic

          -  Uncontrolled asthma which requires steroid inhaler, LABA and does not use leukotriene
             receptor antagonists

          -  Previous nasal surgery for nasal polyp, nasal septum deviation

          -  Acute or chronic rhinosinusitis

          -  Pregnancy and lactation (Urine pregnancy test is allowed and paid by researchers)

          -  Allergic to any kinds of herb

          -  Refusal to participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Minh P. Hoang, Master</last_name>
    <phone>0946148133</phone>
    <phone_ext>+66</phone_ext>
    <email>minhphuochoang@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kornkiat Snidvongs, PhD</last_name>
    <phone>0920134710</phone>
    <phone_ext>+66</phone_ext>
    <email>drkornkiat@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Minh Phuoc Hoang, MD</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minh P Hoang, Master</last_name>
      <phone>0946148133</phone>
      <email>minhphuochoang@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kornkiat Snidvongs, PhD</last_name>
      <phone>0920134710</phone>
      <email>drkornkiat@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Minh Phuoc Hoang, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Zingiber cassumunar</keyword>
  <keyword>Phlai</keyword>
  <keyword>compound D</keyword>
  <keyword>herbal medicine</keyword>
  <keyword>allergic rhinitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Will plan to share information when finishing study</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Plan to complete study in 2 years and will share the data after get publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

